HomeCompareSPPI vs NOBL

SPPI vs NOBL: Dividend Comparison 2026

SPPI yields 14.63% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPPI wins by $29.4K in total portfolio value
10 years
SPPI
SPPI
● Live price
14.63%
Share price
$1.03
Annual div
$0.15
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.2K
Annual income
$3,617.47
Full SPPI calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — SPPI vs NOBL

📍 SPPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPPINOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPPI + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPPI pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPPI
Annual income on $10K today (after 15% tax)
$1,243.90/yr
After 10yr DRIP, annual income (after tax)
$3,074.85/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, SPPI beats the other by $2,862.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPPI + NOBL for your $10,000?

SPPI: 50%NOBL: 50%
100% NOBL50/50100% SPPI
Portfolio after 10yr
$37.6K
Annual income
$1,933.62/yr
Blended yield
5.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SPPI right now

SPPI
Analyst Ratings
6
Buy
7
Hold
1
Sell
Consensus: Hold
Price Target
$0.75
-26.8% upside vs current
Range: $0.75 — $0.75
Altman Z
-14.1
Piotroski
3/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPPI buys
0
NOBL buys
0
No recent congressional trades found for SPPI or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPPINOBL
Forward yield14.63%2.17%
Annual dividend / share$0.15$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52.2K$22.9K
Annual income after 10y$3,617.47$249.78
Total dividends collected$24.9K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SPPI vs NOBL ($10,000, DRIP)

YearSPPI PortfolioSPPI Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$12,163$1,463.41$10,917$217.08+$1.2KSPPI
2$14,678$1,663.56$11,903$221.48+$2.8KSPPI
3$17,582$1,876.20$12,962$225.68+$4.6KSPPI
4$20,913$2,100.33$14,099$229.68+$6.8KSPPI
5$24,712$2,334.81$15,319$233.49+$9.4KSPPI
6$29,020$2,578.43$16,628$237.10+$12.4KSPPI
7$33,881$2,829.86$18,033$240.53+$15.8KSPPI
8$39,341$3,087.76$19,539$243.78+$19.8KSPPI
9$45,446$3,350.75$21,154$246.86+$24.3KSPPI
10$52,244$3,617.47$22,884$249.78+$29.4KSPPI

SPPI vs NOBL: Complete Analysis 2026

SPPIStock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Full SPPI Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this SPPI vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPPI vs SCHDSPPI vs JEPISPPI vs OSPPI vs KOSPPI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.